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Abstract
We examined the contribution of specific EP receptors in regulating cell growth. By RT–PCR and northern hybridiza-
tion, adult human keratinocytes express mRNA for three PGE receptor subtypes associated with cAMP signaling EP ,2 2
.EP , and small amounts of EP . In actively growing, non-confluent primary keratinocyte cultures, the EP and EP3 4 2 4
selective agonists, 11-deoxy PGE and 1-OH PGE , caused complete reversal of indomethacin-induced growth inhibition.1 1
 .  .The EP rEP agonist misoprostol , and the EP rEP agonist 17-phenyl trinor PGE , showed less activity. Similar results3 2 1 2 2
were obtained with agonist-induced cAMP formation. The ability of exogenous dibutyryl cAMP to completely reverse
indomethacin-induced growth inhibition support the conclusion that growth stimulation occurs via an EP andror EP2 4
receptor-adenylyl cyclase coupled response. In contrast, activation of EP receptors by sulprostone, which is virtually3
devoid of agonist activity at EP or EP receptors, inhibited bromodeoxyuridine uptake in indomethacin-treated cells up to2 4
30%. Although human EP receptor variants have been shown in other cell types to markedly inhibit cAMP formation via a3
pertussis toxin sensitive mechanism, EP receptor activation and presumably growth inhibition was independent of adenylyl3
cyclase, suggesting activation of other signaling pathways. q 1998 Elsevier Science B.V.
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1. Introduction
Substantial evidence suggests that endogenous
PGE is important in regulating the growth of both2
normal and neoplastic epithelial cells. Prostaglandin
 .E PGE is a major endogenous product of2 2
prostanoid metabolism in keratinocytes in intact skin
as well as in culture, with increased levels observed
during wound healing and in cutaneous neoplasms
w x1–3 . The importance of PGE in neoplastic devel-2
opment is suggested by the decreased risk for colon
cancer formation associated with the use of non-
 . w xsteroidal antiinflammatory drugs NSAIDs 4 .
Moreover, NSAID’s block tumor formation in tumor
promotion models of skin, intestine, and bladder
w x  .5–8 . The prostaglandin receptor s which are likely
to be involved have not been identified. Because skin
cancer is the most common epithelial malignancy, the
receptor types expressed in human keratinocytes were
defined and their effects on growth were character-
ized in a human tissue culture model.
Recently, four different genes coding for PGE2
 .receptors EP receptors have been cloned and have
been designated as EP , EP , EP , and EP based on1 2 3 4
the relative agonist or antagonist potencies of a num-
ber of different analogues of PGE For reviews, see
w x.9,10 . The EP receptors are coupled to het-
 .erotrimeric GTP binding-proteins G-proteins , and
can also be subgrouped by their respective G-protein
w xinteractions 9,10 . Agonist binding to the EP recep-1
tor has been shown to mobilize intracellular calcium
by a mechanism independent of phospholipase C
w xactivation 9 . The EP and EP receptors have been2 4
shown to stimulate cyclic AMP production via activa-
w xtion of adenylate cyclase 9 . In humans, eight differ-
ent splice variants of the EP receptor have been3
cloned which code for six different functional recep-
w xtor proteins 11–13 . In all of these splice variants,
alternative splicing occurs just 3X to the seventh
transmembrane domain, in a region encoding the
carboxy terminal tail of the receptor which is neces-
sary for G-protein interaction. EP receptor variants3
can mediate multiple signaling pathways. Inhibition
of adenylyl cyclase via a pertussis toxin sensitive
mechanism, stimulation of adenylyl cyclase, activa-
tion of phospholipase C, mobilization of intracellular
calcium, and activation of the nitric oxide-guanylyl
cyclase pathway by a calcium dependent mechanism
w xhave all been described 11,12,14–16 .
Prostaglandin receptors are likely to be important
in regulating normal epidermal growth as well as the
hyperplastic response to wounding and inflammation.
Endogenous PGE levels are seen to rise dramati-2
w xcally following wounding of guinea pig epidermis 2
w xand during inflammation 17 . Exogenous PGE and1
PGE stimulate proliferative activity in human kera-2
w xtinocytes in vitro 18 , in intact skin following topical
w xapplication or intradermal injection 19,20 , and fol-
w xlowing experimental wounding of mouse skin 21 .
Moreover, application of inhibitors of PGE synthesis
w xinhibit the growth of keratinocytes in vitro 22 and in
w xvivo 23 , and inhibit the inflammatory hyperplastic
w xresponse 24 . Growth inhibition in vitro is specifi-
w xcally reversed by PGE 22 . The importance of2
prostaglandins to reepithelialization following
wounding is underscored by experimental animal
 .models of essential fatty acid deficiency EFAD ,
where the dietary precursors necessary for PGE syn-
thesis are not present. In EFAD rats, healing of
partial thickness burns is delayed up to three times
w xlonger 25 .
Most importantly, substantial evidence suggests an
important role for EP receptors in epithelial neopla-
sia. Increased production of PGE is commonly ob-2
served in carcinomas, and increased levels can be
correlated with invasive or metastatic behavior and
w xaggressive growth 3,26–29 . Moreover, administra-
tion of PGE and PGF to syngeneic mice trans-2 2a
planted with chemically induced squamous cell carci-
 .noma SCC markedly enhances the transplantability,
w xgrowth, and cellular atypia of these tumors 30 .
However, different tumors exhibit markedly different
responses to PGE or to inhibitors of PGE produc-2
tion. Inhibitors of prostaglandin production inhibit
w xgrowth of a murine SCC in vivo 31 and a human
w xbreast cancer cell line in vitro 32 . However, indo-
methacin stimulates, and PGE inhibits, growth of2
w xthe human SCC-25 cell line in vitro 33 , and PGE2
fails to stimulate growth in 75–80% of primary
murine mammary tumors, although it stimulates
w xgrowth in normal mammary epithelium 34 . This
heterogeneity of response may be due to altered
PGE receptor expression, since scatchard analysis of2
w3 xH -PGE binding to different human and murine2
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breast cancer cell lines demonstrate different levels of
high-affinity and low-affinity binding sites for PGE2
w x35,36 . Loss of specific high-affinity PGE binding2
sites and increased low-affinity binding sites was
associated with an advanced tumorigenic phenotype
w x35 .
The mechanisms by which PGE acts to regulate
growth is poorly understood, although historical data
suggest that cyclic AMP is likely to mediate the
proliferative response elicited by PGE . Substantial2
evidence exists that cAMP signaling is a positive
w xsignal for growth in epidermis 37,38 and normal
w xmammary epithelium 39 . PGE is known to be a2
w xmajor regulator of cAMP production in skin 40 .
This suggests that the growth promoting activity of
PGE may be mediated via activation of receptors2
linked to cAMP production. However, it is not known
 .which EP receptor subtype s are expressed in the
epidermis, although both human and rodent epidermis
contain specific binding sites for PGE and PGE2 1
w x41,42 . Since cutaneous neoplasias are the most
w xcommon form of human malignancy 43 , we sought
 .to determine the EP receptor subtype s which are
expressed in keratinocytes, and whether these recep-
 .tor s act to regulate cAMP production as well as
keratinocyte growth in response to PGE production.2
These studies provide the foundation for further in-
vestigations into the role of PGE receptors in regu-2
lating hyperplastic and neoplastic epithelial prolifera-
tion.
2. Materials and methods
2.1. Materials
Cyclic adenosine monophosphate EIA kits and the
PGE analogues 11-deoxy-PGE , 17-phenyl trinor1
 .PGE , sulprostone, and PGE alcohol 1-OH-PGE2 1 1
were obtained from Cayman Chemical Ann Arbor,
. MI . Misoprostol was a generous gift of Searle St.
.  .  6 2Louis, MO . Dibutyryl cAMP db-cAMP N ,O -di-
X X .butyryl adenosine 3 :5 -cyclic monophosphate ,
forskolin, PGE , pertussis toxin, 5-bromo-2X-de-2
 .oxyuridine BrdU , saline–sodium citrate buffer
 .SSC , saline–sodium phosphate–EDTA buffer
 .SSPE , 50=Denhardt’s solution, 10% lauryl sulfate
 .SDS , salmon sperm DNA, and indomethacin were
 .obtained from Sigma St. Louis, MO . Sterile phos-
 .phate buffered saline PBS , HEPES buffer, and peni-
cillin–streptomycin were obtained from the Washing-
ton University School of Medicine tissue culture
support center. Dulbecco’s Modified Eagle Medium
 . DMEM high glucose, L-glutamine and without
.sodium pyruvate was obtained from Gibco-BRL
 .  .Gaithersburg, MD . Fetal Bovine Serum FBS was
 .obtained from BioWhittaker Walkersville, MD . Tis-
 .sue culture plates Falcon were obtained from Bec-
 .ton Dickinson Lincoln Park, NJ . Plasmids contain-
ing the EP and EP cDNA’s pcDNAI-hEP and4 3I 4
.pcDNAI-hEP were the generous gift of Dr. K.3I
 .Metters, Merck-Frost Quebec, Canada . Mouse mon-
 .oclonal anti-BrdU clone Bu20a and horseradish per-
oxidase-conjugated rabbit anti-mouse IgG1 were ob-
 .tained from Dako Carpinteria, CA . Peroxoblock
was obtained from Zymed Laboratories South San
.Francisco, CA . Taq DNA polymerase and restriction
enzymes were obtained from Boehringer Mannheim
 . Indianapolis, IN and Gibco-BRL Gaithersburg,
.MD .
2.2. Cell culture and preparation of primary human
keratinocytes
Primary adult human keratinocyte cultures were
obtained from human epidermis removed during re-
w xductive mammoplasty and panniculectomies 22 .
Cells were maintained in Dulbecco’s Modified Eagle
Medium containing 5% fetal bovine serum, penicillin
 .  .100 unitsrml rstreptomycin 100 mgrml , and 25
 w xmM HEPES buffer N- 2-hydroxyethyl piperazine-
X w x.  .N - 2-ethanesulfonic acid growth medium in 95%
air, 5% CO at 378C. All tissue culture plasticware2
was precoated with collagen Vitrogen 100, Collagen,
.Palo Alto, CA .
2.3. Cyclic-AMP assays
Primary adult human keratinocytes were seeded
onto 12-well tissue culture plates. Two days after
 . plating 50–70% confluent , indomethacin 1000=
.stock dissolved in ethanol at a final concentration of
3 mgrml was added to the cultures for 9–16 h to
block endogenous PGE production. For experiments2
using pertussis toxin, pertussis toxin 1000=stock in
.water was added at a final concentration of 20 ngrml.
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Cells were then incubated for 5–9 h at 378C. At the
time of the assay, media was aspirated from the
cultures, and serum-free DMEM prewarmed to 378C
 .was then added containing either vehicle EtOH , or
the desired concentrations of agonist PGE or ana-2
.  .logues 1000=stock in EtOH . For agonist dose-re-
sponse curves, 2 mM isobutyl methyl xanthine
 .IBMX was added to inhibit phosphodiesterase ac-
tivity. After incubation at 378C for the desired time
 .period as specified in figure legends , the media was
rapidly removed and 0.5 ml of ice cold 10% trichloro-
acetic acid in phosphate buffered saline was added to
the cellular monolayer. The cells were then immedi-
ately snap frozen in an ethanol-dry ice bath and
stored at y208C until assayed. Sample preparation
and acetylation as well as the cAMP EIA were done
following the manufacturers protocol Cayman
.Chemical, Ann Arbor, MI . Cyclic AMP levels were
normalized to cellular protein quantitated using the
bicinchoninic acid method BCA Protein Assay,
.Pierce, Rockford, IL .
2.4. Growth Assays: bromodeoxyuridine EIA
Pre-confluent cultures were prepared by seeding
keratinocytes at an initial cell density of 100 000
cellsrcm2 on 24 well plates. Cells were allowed to
attach and grow for two days at which time the cells
were 20–40% confluent. Increasing concentrations of
exogenous PGE or selective agonists were added to2
cells which had been pretreated for 1 h with indo-
 .  .methacin 10 mgrml or vehicle Ethanol . The cells
were then incubated in the presence or absence of
indomethacin and exogenous prostanoids for 2 days,
with daily changes of medium. Ten micromoles of
 .bromodeoxyuridine BrdU was added for the last 9 h
in culture. At the time of BrdU labeling, the mono-
layers were between 50–70% confluent.
The BrdU EIA protocol is a modification of a
w xpreviously reported method 44 . Following ethanol
fixation and treatment with peroxoblock Zymed
.Laboratories, South San Francisco, CA , the cells
were permeabilized with 0.2% Triton X-100 in 25 mM
 .Tris–HCl, 150 mM NaCl, pH 7.6 TBS . Chromoso-
mal DNA was denatured with 95% formamide in
0.15 mM trisodium citrate buffer for 45 min at 708C.
The cells were blocked at room temperature with
TBSr0.1% Tween 20 containing 0.1 mgrml bovine
 .serum albumin blocking buffer , then incubated se-
quentially with primary anti-BrdU diluted 1:50 in
.blocking buffer for 30 min, secondary horseraddish
 .peroxidase HRP -conjugated rabbit anti-mouse-IgG1
 .1:1000 in blocking buffer for 30 min, and finally
substrate 0.2 mgrml o-phenylenediamine in
.TBSr0.1% Tween 20 containing 0.03% H O . The2 2
reaction was stopped with 2 N HCl, and the optical
density measured at 490 nm. Negative control wells
 .background wells were treated identically except
that no BrdU was added. Specific BrdU uptake was
determined by subtracting background wells no BrdU
.added from wells receiving BrdU. Results were nor-
malized to cellular protein quantitated by the bicin-
choninic acid method BCA Protein Assay, Pierce,
.Rockford, IL .
2.5. Re˝erse-transcription polymerase chain reaction
( )RT–PCR
Total RNA was extracted from adult human pri-
mary keratinocytes by the acid guanidinium thio-
w xcyanate–phenol–chloroform method 45 . Primers and
reaction temperature for first strand DNA synthesis
 .are as described in the figure legend Fig. 1 . First
strand DNA synthesis was otherwise performed using
Superscript II reverse transcriptase and the supplied
buffer per the manufacturers instructions Gibco BRL,
.Gaithersburg, MD .
For EP receptor PCR, amplification was per-4
formed on a Thermolyne Temptronic thermocycler
 .BarnsteadrThermolyne, Dubuque, IA for 30 cycles.
Denaturation, annealing, and polymerization tempera-
tures were 958C=1 min, 568C=1 min, and 728C=
30 s, respectively. Reaction components were 1.0 unit
 .Taq DNA polymerase, 20 mM Tris–Hcl pH 8.4 ,
50 mM KCl, 2 mM MgCl , 200 mM dNTP’s, and2
w X10 pmol each of forward primer 5 -ATCTTACT-
X x w XCATTGCCACC-3 and reverse primer 5 -TCTAT-
X xTGCTTTACTGAGCAC-3 in a 50 microliter reac-
tion volume. The 212 bp product encodes nucleotides
1201–1412 in the cDNA sequence described in
w xBastien et al. 46 . The positive control PCR reaction
contained approximately 10 ng of hEP -pcDNAI.4
EP receptor PCR was performed using identical3
conditions except that denaturation and annealing
temperatures were set at 30 s rather than 1 min. The
w X X xforward 5 -GGCACGTGGTGCTTCATC-3 and re-
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Fig. 1. Primary adult human keratinocytes express mRNA for
 .Prostaglandin E receptor subytes EP , EP , and EP by RT–4 3 2
 .PCR. A RT–PCR and southern hybridization with EP receptor4
specific primers from 4 different RNA preparations from individ-
ual 1, a single RNA preparation from individual 2, and 4 separate
RNA preparations from individual 3. Primary adult human kera-
tinocytes were grown on 100mm dishes coated with collagen and
RNA extracted as detailed in Section 2. Reverse transcription was
 .performed using the EP PCR reverse primer see Section 2 at4
378C for 10 min, then at 508C for 50 min. PCR and southern
 .hybridization was performed as described. B RT–PCR and
southern hybidization with primers and conditions specific for the
EP receptor. Samples and reverse transcription conditions are as3
 .stated for Fig. 1 A , except the EP reverse primer was used for3
 .first strand synthesis. C Ethidium-bromide stained 2% agarose
gel of EP RT–PCR products from a RNA isolated from kera-2
tinocytes from a single individual. Lanes 1 and 2 from left to
.right represent duplicate reactions using oligo dT primers for
first strand synthesis. Reverse transcription was done at 378C for
1 h. Lanes 3–5 represent three seperate RNA preparations from
the same individual, with the reverse transcription carried out
 .using the EP PCR reverse primer see Section 2 for first strand2
  .  ..synthesis as above Fig. 1 A and B . Lane L represents the
DNA size ladder.
w X X xverse 5 -GGGTCCAGGATCTGGTTC-3 primers
were designed from sites of considerable DNA se-
quence homology between the EP , EP , and EP1 3 4
receptors. However, the primers specifically ampli-
fied only EP under the conditions utilized. The3
forward primer corresponds to amino acids GTWCFI
in the second extracellular loop of EP receptors. The3
reverse primer corresponds to amino acids LNQILDP
in the seventh transmembrane domain. The 416 bp
product encodes a fragment which is upstream of the
known alternative splice sites for EP splice variants.3
The positive control PCR reaction contained approxi-
mately 10 ng of hEP -pcDNAI.3I
Following electrophoresis in a 2% agarose gel and
staining with ethidium bromide, bands were poorly
visualized in the EP and EP reactions. Therefore,4 3
southern hybridization was performed following
transfer to nylon membranes GeneScreen, NEN Re-
.search Products, Boston, MA using full-length
w32 xP -cDNA probes prepared by random primed label-
w32 x ing with P -dCTP 3000 Cirmmol, Amersham, Ar-
.lington Heights, IL under stringent conditions. Hy-
bridization signals were visualized by autoradiog-
raphy using Kodak Biomax film Eastman Kodak,
.Rochester, NY at y808C overnight with a single
enhancing screen.
EP receptor PCR was performed using a forward2
w X X xprimer 5 -CTTACCTGCAGCTGTACG-3 and re-
w X X xverse primer 5 -GATGGCAAAGACCCAAAGG-3
which amplify a 368 basepair fragment encoding
nucleotides 740 to 1107 of the human EP receptor2
using PCR conditions as described by Regan et al.
w x47 . The PCR product was band purified from a 2%
agarose gel, and the identity confirmed by restriction
digest using 4 separate restriction enzymes Data not
.shown .
2.6. Northern Hybridization
 .qPoly A RNA was prepared using the oligotex
spin column chromotagraphy procedure Qiagen,
.  .qChatsworth, CA . Poly A RNA was elec-
trophoresed in 1% agarose gels containing 0.22 M
formaldehyde and transferred to nylon membranes
 .GeneScreen, NEN Research Products, Boston, MA .
Probes used for hybridization of EP receptor2
mRNA were prepared by random priming Ready-to-
.Go, Pharmacia Biotech, Piscataway, NJ using
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w 32 x a P dCTP 3000 Cirmmol, Amersham, Arlington
.Heights, IL . The EP receptor probe was prepared2
by labeling a 368 bp RT–PCR fragment obtained
from human keratinocyte total RNA as described
above. An EP receptor antisense riboprobe was pre-4
pared from pcDNAI-hEP by digestion with Asp700,4
followed by in vitro transcription with SP6 RNA
polymerase using the Riboprobe Gemini System II
 .Promega, Madison, WI . An EP receptor antisense3
riboprobe was prepared using the SP6 transcriptional
promoter as above from a KspI restriction digest of
pcDNAI-hEP . Riboprobes were labeled with3I
w 32 x a P CTP 800 Cirmmol, Amersham, Arlington
.Heights, IL .
In all cases, the membranes were prehybridized in
6=SSPE, 50% formamide, 1% SDS, and 5=
Denhardt’s reagent at 428C for 1–2 h. Hybridization
was done in the same buffer for 18–24 h at 428C.
Membranes were washed as described in the figure
 .legends Fig. 2 and exposed for 1–3 days in a
Molecular Dynamics phosphoimager PhosphoI-
.mager, model 425B; Sunnyvale, CA .
3. Results
3.1. Primary non-confluent human keratinocytes ex-
press transcripts for the EP , EP , and EP subtypes2 4 3
of prostaglandin E receptors: EP transcripts are2
expressed at higher le˝els than EP transcripts4
To determine which receptors are expressed tran-
scriptionally in non-confluent human keratinocytes in
vitro, RT–PCR was performed which demonstrated
products of the correct size for EP , EP , and EP2 4 3
 .receptors Fig. 1 . No bands were visible in paired
negative control reactions in which reverse transcrip-
 .tase was omitted Data not shown .
In order to establish the relative quantities of the
different receptors and to establish the size andror
number of EP splice variants which are expressed in3
keratinocytes, northern hybridization was performed
 .qusing poly A RNA from cultured non-confluent
 .human keratinocytes Fig. 2 . A band of approxi-
mately 3.1 kb was observed for the EP receptor Fig.2
 ..2 A and a faint band of approximatley 3.8 kb was
 .q w32 x   ..   ..Fig. 2. Northern hybridization of poly A enriched RNA with P -labeled probes specific for EP Fig. 2 A , EP Fig. 2 B , and EP2 3I 4
  ..  .  .qFig. 2 C . A 3 mg poly A RNA hybridized with EP probe as described in experimental procedures. The membrane was washed2
twice at room temperature and once at 428C with 2=SSPE with 0.1% lauryl sulfate. This was followed by a final wash with 1=SSPE
 .  .  .qwith 0.1% lauryl sulfate at 508C. B and C 7mg of poly A RNA hybridized with EP and EP probes as described in experimental3 4
procedures. The membranes were washed sequentially, first at room temperature, then at 428C with 2=SSPE with 0.1% lauryl sulfate
followed by 1=SSPE with 0.1% lauryl sulfate.
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  ..observed for the EP receptor Fig. 2 C . We also4
performed northern hybridization for EP receptors2
 .qon poly A RNA isolated from HaCat cells, a spon-
taneously immortalized keratinocyte cell line, and
SCC-25 cells, a squamous cell carcinoma cell line.
Both cell lines exhibited expression of the 3.1 kb EP2
 .transcript Data not shown . A faint band was also
 .qobserved by northern hybridization of poly A RNA
from HaCat cells with the EP receptor probe Data4
.not shown .
We next attempted to demonstrate the presence of
EP transcripts. Using an EP riboprobe, an intense3 3I
  ..band at approximately 2.4 kb was apparent Fig. 2 B .
This 2.4 kb band was also observed by northern
 .qhybridization using poly A RNA prepared from
 .SCC-25 cells data not shown . In addition, the probe
also hybridized strongly with regions corresponding
with residual 28S and 18S ribosomal RNA ap-
.proximately 1.9 and 5 kb . However, the signal inten-
sity at these sites was considerably less than that
observed with 10 mg of total RNA which was run in
a parallel lane, suggesting that these bands repre-
sented cross-hybridization with ribosomal RNA and
not specific hybridization with the EP receptor.3
Fig. 3. Agonists specific for EP and EP receptors reverse indomethacin-induced growth inhibition in primary adult human keratinocytes.2 4
Receptor-specific agonist stimulation of bromodeoxyuridine uptake in indomethacin-treated non-confluent primary adult keratinocytes
 .approximately 50–70% confluent at the end of experiment . Expressed as percent of control cells which are grown in the absence of
 .indomethacin and agonists. Mean and s.e.m. of 5–7 separate experiments. A Indomethacin inhibits growth to approximately 55% of
 . control cells )sP-0.01, paired t-test . Exogenous PGE addition restores growth to basal growth levels ))sP-0.05 compared2
.with indomethacin control; ANOVA and demonstrates a bell-shaped dose-response pattern, with 100 ngrml PGE less effective than2
 .  .1 ngrml PGE )))sP-0.1, paired t-test . B Growth restoration by EP and EP specific agonists. 1-OH PGE and 11-deoxy2 2 4 1
PGE compared with PGE . ))snot significantly different than the response observed for PGE at 1 ngrml, but significantly different1 2 2
.  .than the indomethacin control, P-0.05, ANOVA . C Growth restoration by EP )EP , EP agonist misoprostol and the EP )EP ,3 2 4 1 2
EP agonist 17-pt-PGE . ))snot significantly different than the response observed for PGE at 1 ngrml, but significantly different4 2 2
. from the indomethacin control, P-0.05, ANOVA . )))s less than the response observed with 1 ngrml PGE , Ps0.095, paired2
.t-test .
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3.2. Re˝ersal of indomethacin-induced growth inhibi-
tion: EP receptor agonist dose-response profiles
This set of experiments was designed to determine
 .which PGE receptor s are involved in the ability of2
exogenous PGE to reverse indomethacin-induced2
growth inhibition in primary cultures of non-con-
w xfluent adult human keratinocytes 22 . Growth was
measured by the incorporation of bromodeoxyuridine
into cellular DNA during S phase of DNA replication
 .by a specific enzyme immunoassay See Section 2 .
 .  .Indomethacin 10 mgrml significantly P-0.01
inhibited growth of non-confluent primary keratino-
cytes to approximately 50% of control levels cells
.  .grown in the absence of indomethacin see Fig. 3 .
Addition of exogenous PGE reversed the indo-2
methacin-induced growth arrest in a dose-dependent
manner, with a maximal effect observed at 1 ngrml
which completely reversed indomethacin-induced
growth inhibition. Higher concentrations of PGE did2
not result in any further increase in growth rates
above control levels, but resulted in a paradoxical
decrease in bromodeoxyuridine incorporation. The
 .highest concentration of PGE tested 100 ngrml ,2
 .showed significantly less activity P-0.1 than the
maximal concentration of 1 ngrml at reversing indo-
methacin-induced growth inhibition.
 .To determine which receptor s mediate this effect,
the ability of different receptor-specific agonists See
.Table 1 to restore indomethacin-induced growth ar-
rest was determined. In Fig. 3, exogenous addition of
11-deoxy PGE , 1-OH PGE , misoprostol, and 17-1 1
phenyl trinor PGE to indomethacin-treated, non-2
confluent keratinocytes all resulted in a significant
reversal of growth inhibition in a dose-dependent
Table 1
Reported specificities of EP receptor agonists references
w x10,16,47,60,61
Receptor Agonist Relative Specificity
PGE EP sEP sEP sEP2 2 4 3 1
11-deoxy PGE EP ,EP )EP )EP1 2 4 3 1
1-OH PGE EP ,EP1 2 4
19-OH PGE EP2 2
Misoprostol EP )EP sEP 4EP3 2 4 1
17-Phenyl trinor PGE EP )EP )EP ,EP2 1 3 2 4
Sulprostone EP )EP 4EP )EP3 1 2 4
Fig. 4. Stimulation of cAMP by 100nM PGE over time in the2
absence of phosphodiesterase inhibitors. Non-confluent primary
adult human keratinocytes were pretreated overnight with indo-
 .methacin 3mgrml and then stimulated for the indicated times
with 100nM PGE in serum free DMEM. Mean and s.e.m. of2
two separate experiments done in triplicate. Cyclic AMP was
normalized to cellular protein.
manner. Agonists with greater specificity for EP and2
EP receptors, 11-deoxy PGE and 1-OH PGE ,4 1 1
caused nearly complete reversal of indomethacin-
induced growth inhibition at a concentration of
100 ngrml. At this concentration, growth reversal
was not significantly different from the maximal
 .response for PGE 1 ngrml . In contrast, the maxi-2
 .mal response for misoprostol EP )EP , observed3 2
at an agonist concentration of 100 ngrml, was less
 . than that for PGE Ps0.095; paired t-test Fig.2
 ..3 C . All agonists, with the exception of 17-phenyl
trinor PGE , showed a bell-shaped dose-response2
profile as was seen with PGE , with bromodeoxyuri-2
dine uptake reaching a maximal level, followed by
decreased uptake at higher concentrations. The rank
order of activity of all agonists was PGE )11-deoxy2
PGE ) 1-OH PGE ) 17-phenyl trinor PGE s1 1 2
misoprostol.
3.3. Agonist dose-response profiles for acti˝ation of
adenylyl cyclase
In the above experiments, EP and EP selective2 4
agonists showed the greatest ability to reverse indo-
methacin-induced growth inhibition. Since EP and2
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EP receptors are known to stimulate cAMP produc-4
tion, and cAMP has been suggested to be a positive
growth signal in keratinocytes, we examined the abil-
ity of the different receptor agonists to stimulate
cAMP production. Fig. 4 illustrates a typical time
course experiment measuring cyclic AMP levels in
pre-confluent keratinocytes in response to 100 nM
PGE in the absence of phosphodiesterase inhibitors.2
To determine which receptor mediates this in-
crease in cAMP levels, cAMP dose-response curves
elicited by a panel of selective agonists for the vari-
  .  ..ous EP receptor types were generated Fig. 5 A – C .
A common phenomenon associated with G-protein
coupled receptors is the desensitization and down-
regulation of receptor-mediated second messenger re-
w xsponse pathways 10 . This phenomenon has been
w xobserved in PGE receptors 48,49 . In preliminary2
experiments, down-regulation or desensitization of
the cAMP response to PGE was observed. Cells2
which had been pretreated with indomethacin to block
receptor down-regulation or desensitization by en-
dogenously produced PGE showed approximately a2
4-fold increased cAMP response in the presence of
.IBMX to exogenous PGE than cells not treated2
 .with indomethacin Data not shown . Therefore, to
maximize the observed difference in cAMP responses
elicited by the different receptor agonists, dose-re-
sponse profiles were done in cells pretreated for 9 h
in the presence of 3 mgrml indomethacin.
 .In Fig. 5 A , dose-response profiles for the EP2
and EP receptor agonists 11-deoxy PGE and 1-OH4 1
PGE , and the EP receptor agonist 19-OH PGE ,1 2 2
are compared with the dose-response profile for
PGE . PGE stimulates a dose-dependent increase in2 2
Fig. 5. Agonists specific for EP and EP receptors stimulate cAMP production in primary adult human keratinocytes. Agonist2 4
 .dose-response curves for cAMP stimulation in the presence of 2 mM isobutyl methyl xanthine IBMX , a phosphodiesterase inhibitor.
 .Non-confluent primary adult human keratinocytes pretreated overnight with indomethacin 3 mgrml were stimulated for 15 min with
 .increasing concentrations of agonist with indomethacin 3 mgrml in serum free DMEM. Control cells received indomethacin alone.
Results are expressed as the mean and standard deviation of two separate experiments using pooled triplicate wells for each cAMP
determination.
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 .cAMP levels with an EC of 7.8 ngrml 27.3 nM50
which is in general agreement with the reported EC50
w xfor EP receptors in other cell types 47,49 . The2
curve for 11 deoxy-PGE was similar to that for1
PGE However, while 19-OH PGE and 1-OH PGE2. 2 1
exhibited similar dose-response curves, both showed
decreased potency for cAMP stimulation when com-
pared with PGE .2
 .  .Fig. 5 B and C demonstrates the cAMP dose-re-
sponse curves generated by the EP )EP specific1 2
agonist 17-phenyl trinor PGE , the EP )EP rEP2 3 2 4
agonist misoprostol, and the EP rEP agonist sulpro-3 1
stone. Compared with the dose-response profile for
PGE , 17 phenyl trinor PGE was less active. How-2 2
ever, 17 phenyl trinor PGE exhibited greater po-2
tency than misoprostol, 19-OH PGE , or 1-OH PGE .2 1
Misoprostol elicited a cAMP response similar to that
for 19-OH PGE and 1-OH PGE . Sulprostone did2 1
not elicit a cAMP response except at the highest dose
 .100 mgrml . The relative potency for the different
agonists were in the order 11d-PGE sPGE )171 2
phenyl trinor PGE )19-OH-PGE s1-OH-PGE s2 2 1
misoprostol))sulprostone.
Activation of EP receptors has been shown to3
dramatically inhibit forskolin-induced cAMP produc-
w xtion with IC ’s of 0.1 to 3 nM 11 . This activity is50
blocked by pertussis toxin, suggesting interaction with
heterotrimeric G-proteins containing the G subunit.ia
To examine this, we stimulated non-confluent kera-
tinocytes with forskolin, a direct activator of adenylyl
cyclase, both in the presence and absence of increas-
ing concentrations of sulprostone. Sulprostone was
unable to decrease the cAMP production in response
to forskolin up to concentrations of 100 ngrml ap-
.  .prox. 350 mM data not shown . Moreover, pretreat-
ment with pertussis toxin had no effect on the dose-
response curves for cAMP production using the EP3
agonists misoprostol and sulprostone data not
.shown .
3.4. Indomethacin-induced growth inhibition is re-
˝ersed by exogenous addition of dibutyryl cAMP
To demonstrate whether the increase in cAMP
levels obtained by activation of EP andror EP2 4
receptors is the signaling mechanism involved in
stimulating BrdU incorporation, we next sought to
Fig. 6. Dibutyryl cAMP dose-dependently restores growth in
 .indomethacin 10 mgrml treated non-confluent keratinocytes.
Cells were treated with dibutyryl cAMP in the presence and
absence of indomethacin for two days with daily changes of
media and reagents. Growth was measured by bromodeoxyuri-
dine uptake by EIA as described in experimental procedures.
Expressed as percent of control cells no indomethacin and no
.dibutyryl cAMP . Mean and standard deviation of two experi-
ments done in quadruplicate.
determine whether BrdU uptake could be restored to
control levels in indomethacin-treated keratinocytes
by treatment with a cell permeable analogue of cAMP
 .dibutyryl cAMP . If cAMP is required for PGE2
stimulated growth, then addition of exogenous cAMP
should reverse indomethacin-induced growth inhibi-
tion. Dibutyryl cAMP was shown to dose-depen-
dently restore growth to control levels in indo-
 .methacin treated keratinocytes Fig. 6 .
3.5. Sulprostone inhibits bromodeoxyuridine uptake
in indomethacin-treated non-confluent keratinocytes
Sulprostone, which is virtually devoid of EP or2
EP binding activity, is a potent agonist for EP and4 3
EP receptors. In Fig. 7, sulprostone induced a dose-1
dependent decrease in BrdU uptake up to 30% greater
at 0.1 ngrml than cells treated with indomethacin
 .alone Ps0.118; ANOVA . At concentrations higher
than 10 ngrml, the decrease in BrdU uptake began to
( )R.L. Konger et al.rBiochimica et Biophysica Acta 1401 1998 221–234 231
Fig. 7. Sulprostone inhibits growth of primary adult human
keratinocytes in the absence of endogenous PGE . Dose-response2
growth assay by bromodeoxyuridine uptake EIA using increasing
concentrations of the EP )EP agonist sulprostone compared3 1
with PGE . Results and experimental protocol are as described in2
Fig. 3 and experimental procedures. Results are expressed as the
mean and s.e.m. of 5 separate experiments for sulprostone and 7
  ..experiments for PGE see Fig. 3 A .2
normalize to levels obtained in the indomethacin-
treated control cells.
4. Discussion
Mechanistic studies of the role of PGE in vivo2
are complicated by the difficulty in dissecting direct
effects of PGE on cellular proliferation from indi-2
rect contributions from increased blood flow and
inflammatory infiltrates. Previously, it was shown
that endogenous PGE stimulates growth of non-con-2
w xfluent human keratinocytes in vitro 22 . Ker-
atinocytes growing in non-confluent culture pheno-
typically and biochemically resemble the ‘‘activated’’
basal cell population responsible for reepithelializa-
w xtion following cutaneous wounds 50,51 , and after
w xapplication of non-mutagenic tumor promoters 7 .
Thus, non-confluent cultures offer an attractive model
for studying the receptor-mediated growth promoting
effects of PGE on activated keratinocytes. In this2
report, we demonstrate by RT–PCR and northern
hybridization that non-confluent primary adult human
keratinocytes express message for EP , EP , and EP2 4 3
receptors. Previously, PGE was shown to increase2
w xcAMP levels in human and rodent skin 40–42 .
However, demonstration of specific PGE receptor2
subtype expression in skin has not been reported. In
 .addition, the receptor subtype s and signaling mech-
anism which mediate the proliferative response is
unknown. We demonstrate that EP , and possibly EP2 4
receptors, mediate the growth promoting effects of
endogenous PGE production, and that this effect is2
dependent on cAMP signaling. Moreover, the con-
 .centration of PGE 1 ngrml which gives a maximal2
growth response in indomethacin-treated keratino-
 .cytes Fig. 3 is in general agreement with both the
observed concentrations of endogenous PGE pro-2
duced by non-confluent cultures 5.09 "
3.29 ngrmlr24 h; mean and standard deviation, ns
.11 and the EC for stimulation of adenylyl cyclase50
 .7.8 ngrml . These observations, plus the observed
bell-shaped growth response curve suggest that PGE2
levels are tightly regulated to maximize growth and
prevent receptor down-regulation. In addition, kera-
tinocytes also express at least one splice variant of
the EP receptor subtype, activation of which causes3
growth inhibition in a cAMP-independent manner.
 .By northern analysis Fig. 2 , the EP receptor2
w xsubtype, as described by Regan et al. 47 , appears to
be present at much higher levels than the levels
observed for the EP receptor subtype, suggesting4
that the EP receptor is the predominant receptor2
responsible for both the observed growth effects Fig.
.  .3 and the stimulation of cAMP production Fig. 5
by agonists specific for EP and EP receptor sub-2 4
types. However, little is known about post-transcrip-
tional regulation of these receptors. Since mRNA
expression does not always correlate with protein
levels, a significant contribution by EP receptors4
cannot be excluded. In addition, a band of approxi-
mately 2.4 kb was observed by northern hybridization
using an EP riboprobe. The size of this band is in3I
agreement with a 2.4–2.5 kb band observed by north-
ern blotting in previous studies of other tissue types
w x11–13 .
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 .To determine which receptor subtype s mediate
 .proliferation, and whether these same subtype s also
stimulate adenylyl cyclase, agonist dose-response
profiles were generated using the agonists listed in
Table 1. Agonists reported to have higher degrees of
selectivity for EP andror EP receptor activation2 4
stimulated cAMP production as well as reversed
indomethacin-induced growth inhibition. The in-
crease in cAMP observed for these agonists appears
to be a necessary signal for PGE stimulated growth,2
since addition of exogenous dibutyryl cAMP was
also able to completely reverse indomethacin-induced
 .growth arrest Fig. 6 . Taken together, this data indi-
cates that proliferation is stimulated by EP andror2
EP receptors coupled to adenylyl cyclase activation,4
although the northern data suggest that EP receptors2
are the predominant receptor type mediating this
effect. However, it is unclear whether the observed
growth effects are mediated by direct stimulation of
cells to enter the cell cycle, or by blocking entry into
terminal differentiation or apoptosis. The ability of
cAMP-elevating agents to inhibit epidermal growth
 .factor EGF -induced differentiation has been sug-
gested in the epidermoid carcinoma cell line A431
w x52,53 . In addition, keratinocytes undergo apoptosis
w x54 , and a role for PGE and cAMP in negative2
regulation of apoptosis is demonstrated in other cell
w xtypes 55,56 .
Contrary to the growth promoting effects of
EP rEP receptors, sulprostone, which is virtually2 4
devoid of activity at either EP or EP receptors,2 4
caused a decrease in bromodeoxyuridine uptake when
compared with indomethacin-treated cells alone. This
suggests that isolated activation of EP receptors3
constitutes a negative growth signal. However, this
effect does not appear to result from direct inhibition
of adenylyl cyclase. Sulprostone had no effect on
 .basal cAMP production Fig. 5 , nor did it inhibit the
cAMP response elicited by forskolin, a direct activa-
tor of adenylyl cyclase, both in the presence and
 .absence of pertussis toxin data not shown . It is
possible that the growth inhibitory effects observed
with sulprostone are in part mediated by EP recep-1
tors. Using RT–PCR, preliminary data suggests that
the EP receptor is expressed in normal adult conflu-1
ent keratinocytes, HaCat cells, and in epidermoid
 .  .carcinoma cells A431 data not shown . However,
the rather potent growth stimulating activity of 17-
phenyl trinor PGE , with rank agonist potency of2
EP )EP )EP , and the relatively poor growth1 2 3
stimulatory activity of misoprostol EP )EP )EP3 2 4
.)EP , suggests that the EP receptor subtype is1 3
primarily responsible for the observed growth inhibi-
tion.
The absence of any observable effect of EP recep-3
tor activation on cAMP production suggests that the
growth inhibitory activity of sulprostone could be the
result of activation of alternative second messenger
cascades, possibly activation of phospholipase C
w xandror intracellular calcium mobilization 11,12,16 .
Negative growth regulation by EP receptors could3
result from direct mitogenic inhibition, increased
apoptosis, or increased rate of entry into terminal
differentiation. PGE receptors acting through phos-2
pholipase C and calcium signaling are likely to be
important regulators of keratinocyte differentiation
since calcium and protein kinase C are potent induc-
w xers of keratinocyte differentiation 57–59 .
In conclusion, these observations are relevant to
our understanding of the role of PGE in regulating2
normal, hyperplastic, and neoplastic cell growth. In
parallel with the observations reported here, both
PGE and cAMP stimulate proliferation in normal2
w xmammary epithelial cells 34,39 , but PGE has vari-2
able activity in stimulating growth of different breast
w xcancer cell lines 32,34,35 . This heterogeneity of
response may be due to altered PGE receptor ex-2
w xpression. Planchon et al. 35 , using scatchard analy-
w3 xsis of specific H -PGE binding, demonstrated that2
 .Ha-ras transfected MCF-7 MCF-7ras human ductal
breast carcinoma cells exhibited more than 80% loss
 .of high-affinity PGE binding sites K s0.1 nM2 d
and a two-fold increase in low-affinity binding sites
 .K s35 nM compared with non-transfected MCF-7d
cells. Moreover, the MCF-7ras cells exhibit an ad-
vanced tumorigenic phenotype. The presence of
 .high-affinity binding sites K of 0.1 nM in thed
 .human breast cancer cell line MCF-7 is consistent
with the K observed for EP receptor subtypesd 3
w x9–11 . The low-affinity binding sites may represent
EP receptors, since PGE was shown to stimulate2 2
w xcAMP production 35 . Moreover, the loss of these
high-affinity receptors and increase in low-affinity
receptors was associated with increased tumorigenic-
ity and a more aggressive histologic phenotype. In
this report, we have shown that selective stimulation
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of PGE receptors modulate epithelial cell growth,2
thus raising the possibility that alterations of normal
receptor number or function could be associated with
increased tumorigenicity, tumor proliferation, or in-
vasive behavior in epithelial malignancies.
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